AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSMIntellia Therapeutics, Inc. • February 23rd, 2024 • In vitro & in vivo diagnostic substances
This Amendment No. 1 to the Open Market Sale AgreementSM, dated as of February 23, 2024, is entered into by and between Intellia Therapeutics, Inc. (the “Company”) and Jefferies LLC (the “Agent”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Sales Agreement (as defined below).
